PI3K Alpha/Beta Inhibitor BAY1082439

Known as: BAY1082439

An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K… Expand

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2018

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439.

Yongkang Zou, Zhi Qi, +5 authors Hong Wu
Molecular cancer therapeutics
2018

Targeting the PI3K pathway is a promising strategy for treating prostate cancers with PTEN-loss. However, current anti-PI3K… Expand

Is this relevant?